Hidradenitis suppurativa treatment accepted for NHS use

Adalimumab (Humira) has been approved by NICE for patients with active moderate to severe hidradenitis suppurativa who have failed to respond to conventional systemic therapy.

Hidradenitis suppurativa is a painful condition that can dramatically affect patients' psychological wellbeing and quality of life. | SCIENCE PHOTO LIBRARY
Hidradenitis suppurativa is a painful condition that can dramatically affect patients' psychological wellbeing and quality of life. | SCIENCE PHOTO LIBRARY

NICE's approval of adalimumab for the treatment of hidradenitis suppurativa is contingent on the manufacturer providing the TNF-inhibiting antibody at the price agreed in the patient access scheme.

Further information
View Humira drug record
NICE technology appraisal TA392
MIMS Dermatology Clinic

Healthcare professionals should assess the response to adalimumab after 12 weeks of treatment, and only continue if there is clear evidence of response, defined as:

  • a reduction of 25% or more in the total abscess and inflammatory nodule count, and
  • no increase in abscesses and draining fistulas.

Approved in 2015 for the treatment of hidradenitis suppurativa, Humira is the first licensed option for the chronic systemic inflammatory disorder, which is characterised by inflamed nodules, boils and abscesses located particularly around the groin and underarm.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in